Solving the Insoluble

Our mission is to enable new oral medicines by solving bioavailability issues. Poor drug solubility affects almost all of the small molecules currently in development and results in many viable medications never reaching patients. SeraNovo’s platform is a fundamentally new and superior approach to this problem.


By coupling a purpose designed eutectic solvent with polymeric precipitation inhibitors SeraNovo can achieve high oral bioavailability for poorly soluble drug molecules. Our formulations are composed only of constituents that are GRAS accredited and/or broadly used in the pharmaceutical industry.

View our Technology


Our focused offering de-risks the development program by solving a specific problem, poor drug solubility. By providing a staged approach to formulation development the risk is low but the potential payoff is high. Follow the link to see how SeraNovo can assist your pharmaceutical development.

View our Services

Bioavailability Enhancement

Proven significant bioavailability improvement in vivo

Single Formulation

One formulation from preclinical through market release.

Dose Flexibility

High solubility liquid formulations offer total dose control.

Easy scale up

Our technology is quick, simple and inexpensive to scale.

Broad compatibility

Proven efficacy across a diverse range of small molecule drug types.

Latest News

SeraNovo Enters into License Agreement with Carna Biosciences for Development of Oral Formulation of Carna’s Kinase inhibitor

By |October, 2019|

SeraNovo B.V. today announced that it has signed an License Agreement with Carna Biosciences, Inc., a company engaged in drug development specializing in the development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly continue to develop an oral formulation with an increased bioavailability. Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on constituents that are for oral administration or broadly used in the industry. The final formulation includes an optimized combination of a DES, one or more polymeric precipitation inhibitors and Carna’s Kinase inhibitor.

Read the full press release

Dr Martin Bakker joins SeraNovo

By |January, 2019|

Experienced business developer Martin Bakker has joined SeraNovo effective immediately. Following substantial recent progress, we have added Martin to our business development team. Martin has a proven track record within the formulation industry and is enthusiast about joining our team and expanding our commercial reach.

SeraNovo wins Venture Challenge 2018

By |November, 2018|

Chrétien Herben, director of the LifeSciences@Work Accelerator, announced SeraNovo as winning team of the 20th edition of the Venture Challenge. The Leiden-based start-up SeraNovo helps pharmaceutical companies increase bioavailability of their drugs through an innovative formulation platform.

According to the Venture Challenge jury, the platform addresses a great need of the pharmaceutical industry. SeraNovo has impressed the jury with their expertise and presentation skills at the Venture Challenge finals at Loyens & Loeff last week.

Solving the Insoluble

Inquire about the possibilities of solving your solubility problems now!

Contact Us